

Clinical trials of ibesartan

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
ibesartan vs placebo			
I-PRESERVE (McMurray), 2008 [NCT00095238] n=2067/2061 follow-up: 49.5 months	ibesartan 300mg daily versus placebo	patients with NYHA II, III, or IV heart failure and an ejection fraction of at least 45%	Parallel groups double blind Western Europe, Eastern Europe, North America, South America, South Africa, and Australia

More details and results :

- angiotensin-receptor blockers for heart failure in patients with preserved-LVEF heart failure at <http://www.trialresultscenter.org/go-Q233>
- inhibition of the renin-angiotensin system (ACEI or ARB) for heart failure in patients with preserved-LVEF heart failure at <http://www.trialresultscenter.org/go-Q234>

References

I-PRESERVE (McMurray), 2008:

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4;359:2456-67 [19001508] [10.1056/NEJMoa0805450](https://doi.org/10.1056/NEJMoa0805450)

McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008 Feb;10:149-56 [18279770]

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4;359:2456-67 [19001508]

2 heart failure with preserved LVEF

Trial	Treatments	Patients	Trials design and methods
ibesartan vs placebo			
I-PRESERVE (McMurray), 2008 [NCT00095238] n=2067/2061 follow-up: 49.5 months	ibersatan 300mg daily versus placebo	patients with NYHA II, III, or IV heart failure and an ejection fraction of at least 45%	Parallel groups double blind Western Europe, Eastern Europe, North America, South America, South Africa, and Australia

More details and results :

- All mechanism for heart failure with preserved LVEF in all type of patients at <http://www.trialresultscenter.org/go-Q237>

References

I-PRESERVE (McMurray), 2008:

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4;359:2456-67 [19001508] [10.1056/NEJMoa0805450](https://doi.org/10.1056/NEJMoa0805450)

McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008 Feb;10:149-56 [18279770]

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4;359:2456-67 [19001508]

Entry terms: irbesartan, Aprovel, Avapro, Karvea